With an inhibitor of the Trk family of receptor tyrosine kinases in phase I, Loxo Oncology Inc. priced an upsized initial public offering (IPO) of about 5.2 million shares at $13 each, raising about $67.6 million for an effort to come up with a best-in-class compound.